Загрузка...
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
BACKGROUND: The global EINSTEIN DVT and PE studies compared rivaroxaban (15 mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K antagonist therapy and demonstrated non-inferiority for efficacy and superiority for major bleeding. Owing to differences in targeted anticoa...
Сохранить в:
| Опубликовано в: : | Thromb J |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4339301/ https://ncbi.nlm.nih.gov/pubmed/25717286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12959-015-0035-3 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|